[A18-03] Daratumumab (multiple myeloma) - Addendum to Commission A17-40
Last updated 15.02.2018
Commission awarded on 08.01.2018 by the Federal Joint Committee (G-BA).
Adults with multiple myeloma who have received at least one previous treatment
Combination with lenalidomide and dexamethasone or with bortezomib and dexamethasone: proof of considerable added benefit. Monotherapy: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.